Streetbeat News

Analyst Ratings

HIBB

Benchmark analyst John Lawrence downgrades Hibbett (NASDAQ:HIBB) from Buy to Hold.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:30 am

OCS

HC Wainwright & Co. analyst Yi Chen has maintained a Buy rating on Oculis Holding (NASDAQ:OCS) but lowered the price target from $29 to $28.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:27 am

SIRI

Sirius XM Holdings' stock trades higher following an upgrade from Hold to Buy by Pivotal Research, despite a reduction in the price target from $5.05 to $4.90.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:23 am

AEYE

HC Wainwright & Co. analyst Scott Buck has reiterated a Buy rating on AudioEye (NASDAQ:AEYE) and maintained a $17 price target.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:19 am

CLIR

HC Wainwright & Co. analyst Amit Dayal has reiterated a Buy rating on ClearSign Technologies (NASDAQ:CLIR), maintaining a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:16 am

TSLA

Mizuho analyst Vijay Rakesh maintains a Neutral rating on Tesla (TSLA) and lowers the price target from $195 to $180.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:15 am

TSLA

Tesla shares are trading higher after the company reported its Q1 earnings. Furthermore, B of A Securities upgraded Tesla's stock from Neutral to Buy, indicating a positive outlook on the company's financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:14 am

TSLA

B of A Securities analyst John Murphy upgrades Tesla (NASDAQ:TSLA) from Neutral to Buy and maintains a $220 price target.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:12 am

CX

B of A Securities analyst Carlos Peyrelongue downgraded Cemex (NYSE:CX) from Buy to Neutral while maintaining the price target at $9.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:11 am

DAWN

HC Wainwright & Co. analyst Andres Maldonado reiterated a Buy rating on Day One Biopharmaceutical (NASDAQ:DAWN) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:10 am